News from protagonist therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 03, 2021, 07:00 ET Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results

Protagonist Therapeutics, Inc. (Nasdaq: PTGX), today announced it will host a conference call and webcast on Wednesday, March 10 at 4:30 pm ET/1:30...

Mar 02, 2021, 07:00 ET Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in...

Feb 26, 2021, 18:20 ET Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on February 26, 2021, it issued an inducement award to Jami Taylor, the Company's...

Feb 16, 2021, 07:00 ET Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in ...

Jan 29, 2021, 18:22 ET Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 29, 2021, it issued an inducement award to Paula O'Connor, M.D., the...

Jan 04, 2021, 07:00 ET Protagonist Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the ...

Dec 16, 2020, 07:30 ET Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-235 (JNJ-77242113)

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first subject has been dosed in a Phase 1 study of PN-235 (also referenced as...

Dec 15, 2020, 16:30 ET Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced...

Dec 10, 2020, 23:10 ET Protagonist Therapeutics, Inc. Announces Pricing of $100 Million Public Offering of Common Stock

Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced...

Dec 10, 2020, 07:30 ET Protagonist Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten...

Dec 07, 2020, 10:00 ET Protagonist Announces Results of Large-Scale Analysis of Current Treatment Patterns Revealing Significant Opportunity to Improve the Standard of Care for Patients with Polycythemia Vera Across Broad Population Categories

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the results of a large-scale analysis of real world treatment patterns for polycythemia...

Dec 06, 2020, 14:45 ET Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced additional updated results from the ongoing Phase 2 study of PTG-300 in patients with...

Dec 02, 2020, 07:00 ET Protagonist's Hepcidin Mimetic Candidate PTG-300 Receives Fast Track Designation from the U.S. Food and Drug Administration for Development in the Treatment of Polycythemia Vera

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to...

Dec 01, 2020, 16:30 ET Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 30, 2020, it issued an inducement award to Michelle Landolfi, Ph.D., the ...

Nov 30, 2020, 07:00 ET Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will host a conference call to provide a research and development (R&D) ...

Nov 25, 2020, 07:00 ET Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in ...

Nov 11, 2020, 16:30 ET Protagonist Therapeutics to Participate in the Jefferies Virtual 2020 London Healthcare Conference

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in...

Nov 04, 2020, 16:54 ET Protagonist Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the third quarter ended September 30, 2020, and provided a...

Nov 04, 2020, 10:20 ET Protagonist Therapeutics to Present Updated Clinical Data for Hepcidin Mimetic PTG-300 in Polycythemia Vera at the American Society for Hematology (ASH) 2020 Annual Meeting

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced the acceptance of one oral and four poster presentations at the American Society for...

Oct 30, 2020, 18:27 ET Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on October 31, 2020, it issued an inducement award to Nora Boyer, the Company's...

Oct 29, 2020, 16:30 ET Protagonist Therapeutics Announces Advancement of Oral IL-23 Receptor Antagonists Program in Collaboration with Janssen

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that two additional oral peptide IL-23 receptor antagonist candidates from its...

Oct 21, 2020, 07:00 ET Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that the European Medicines Agency (EMA) has granted orphan drug designation for PTG-300 ...

Sep 17, 2020, 16:30 ET Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in...

Sep 15, 2020, 16:48 ET Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on September 15, 2020, it issued an inducement award to Matthew Gosling, the...

Sep 10, 2020, 16:30 ET Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in...